Skip to main content
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. — Investor Relations & Filings

Ticker · ALLO ISIN · US0197701065 US Manufacturing
Open in API
Filings indexed 523 across all filing types
Latest filing 2019-09-10 Director's Dealing
Country US United States of America
Listing US ALLO

About Allogene Therapeutics, Inc.

https://allogene.com/

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies. The company engineers T cells from healthy donors to create "off-the-shelf" treatments for cancer and autoimmune diseases. This approach is designed to enable on-demand availability, scalability, and reliability, contrasting with autologous therapies that use a patient's own cells. Allogene's pipeline utilizes multiplex gene-engineering and gene-editing capabilities. Its key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for clear cell renal cell carcinoma, and ALLO-329 for autoimmune disease.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2019-09-10 English
PRIMARY DOCUMENT
Director's Dealing
2019-09-10 English
PRIMARY DOCUMENT
Director's Dealing
2019-09-05 English
PRIMARY DOCUMENT
Director's Dealing
2019-09-05 English
10-Q
Interim / Quarterly Report Q2 2019
2019-08-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions "Item 2.02 Results of Operations and Financial Condition" and references a press release with financial results for the quarter ended June 30, 2019. The document itself is short (3959 characters) and primarily serves to announce the financial results and provide a press release as an exhibit. It does not contain detailed financial statements or comprehensive analysis itself, but rather a summary and reference to the press release. According to the rules, such a document is best classified as an Earnings Release (ER) because it announces quarterly financial results highlights. It is not an Interim/Quarterly Report (IR) because it lacks substantive financial data and analysis, nor is it a Regulatory Filing (RNS) since it is a standard 8-K earnings announcement. Therefore, the appropriate classification is ER with high confidence.
2019-08-07 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.